Found 14 dm-cardiology-waxman trials
A listing of dm-cardiology-waxman medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a prospective global multicenter long-term observational study designed to document the clinical outcomes of patients with hereditary transthyretin-mediated amyloidosis or wild-type transthyretin-mediated amyloidosis and the safety of patisiran (Onpattro) when used in patients with ATTRv amyloidosis. This is data collection study only and no study medication no visits …
This open-label study is designed to evaluate the long-term safety and tolerability of acoramidis in participants with ATTR-CM, administered on a background of stable heart failure therapy. This study follows the randomized, double-blind, placebo-controlled Study AG10-301 which was designed to examine safety and efficacy in this same population.
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE. Up to 1200 subjects with intermediate-risk acute PE will be randomized. All subjects who sign informed consent and who meet all of the inclusion criteria and none …
This is a multicenter, randomized, quadruple-blind, sham controlled, 2-part, embedded IDE clinical trial. The main objective is to evaluate the efficacy and safety of Cardiac Contractility Modulation (CCM) therapy in patients with symptomatic HF with LVEF 40-60%. The study is divided into 3 phases, screening, randomization (where 2/3 will be …
The INTEGRA D study will evaluate the safety and efficacy of the CCM D System in patients with heart failure symptoms despite being on GDMT and have an LVEF 40%.The This is designed as a single arm, prospective, multicenter study of 300 subjects that will establish that the device can …
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group, event-driven, superiority, group sequential study to evaluate the efficacy and safety of milvexian in participants enrolled within 7 days of an Acute Coronary Syndrome. Participants will receive either milvexian/ placebo on a background of standard-of-care antiplatelet therapy. The total …
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of amyloid depleter ALXN2220 compared to placebo in adult participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).Approximately 1000 participants will be enrolled and randomized to receive either ALXN2220 or placebo in a 2:1 ratio. Participants will receive …
This is a prospective, multicenter,randomized, nonblinded study to evaluate the safety and effectiveness of the Aortix System versus standard of care medical therapy in patients hospitalized with ADHF and persistent congestion despite usual medical management and who are not being considered for nearterm advanced HF therapy (i.e., LVAD placement or …
To evaluate the efficacy of NTLA-2001, as measured by the composite risk of CV-related mortality and CV events (urgent HF visits and hospitalizations due to HF, MI, arrhythmia, or stroke), compared to placebo Composite endpoint comprising Cardiovascular related mortality and frequency and timing of Cardiovascular events (urgent Heart Failure visits …
This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of repeat doses of IgPro20 in subjects with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome). Eligible subjects will be randomized in a 2:1 ratio to receive subcutaneous (SC) infusions of IgPro20 …
1 - 10 of 14
- 1
- 2
